Waystar Weighs Sale as Software Sector Faces Market Challenges
Waystar explores strategic options, including a sale, amid declining market value.
Healthcare software company Waystar is reportedly considering strategic alternatives, including a potential sale, according to sources familiar with the situation. This development comes just two years after Waystar became a publicly traded entity on the New York Stock Exchange.
Exploring Strategic Options Amid Market Decline
Based in Lehi, Utah, and Louisville, Kentucky, Waystar has engaged investment bank Evercore to guide the exploration of its strategic options. The process is in its preliminary stages, and sources caution that a sale is not guaranteed. The company's market value has dipped to approximately $4.8 billion following a 24% decrease in its stock value this year, reflecting a broader downturn in the software industry.
The company's decision to explore a sale may test whether investor interest in software firms is reviving. Initially, Waystar positioned itself as a healthcare software provider, emphasizing automation and administrative efficiency, aiming for the valuation premiums often seen with tech companies. This approach initially resonated with investors, driving shares from $20 to a peak of $45 in 2025. However, concerns about the impact of artificial intelligence advancements on software companies have recently pressured the stock.
Background and Ownership Structure
Waystar was established in 2017 through the merger of Zirmed and Navicure, both healthcare revenue management companies. The company's primary shareholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT holds a 13% stake, followed by CPPIB with 10%, and BlackRock Institutional Trust Company owning 8%, based on data from LSEG.
Despite the company's strategic positioning in the healthcare software sector, market fluctuations and investor concerns have led to its current situation. None of the major stakeholders, including EQT and CPPIB, have commented on the potential sale, maintaining a stance of discretion as the evaluation process continues.
Waystar's exploration of a sale and other options highlights the challenges faced by software companies navigating a volatile market landscape. The outcome of this process will be closely watched by industry analysts and investors, as it may signal broader trends in the valuation and strategic direction of tech-focused healthcare firms.